ALEXIS VENTURA: Open Payments
NPI 1609410463 · RANCHO CUCAMONGA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,725 in 137 payments from 15 companies in 2025. Trend: 2023 $3,427 · 2024 $2,153 · 2025 $2,725
Food & beverage: $2,725
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $410 |
| Otsuka America Pharmaceutical, Inc. | 19 | $394 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $385 |
| Teva Pharmaceuticals USA, Inc. | 14 | $298 |
| Janssen Pharmaceuticals, Inc | 11 | $225 |
| Alkermes, Inc. | 9 | $195 |
| Tris Pharma Inc | 12 | $175 |
| Neurocrine BioSciences, Inc. | 6 | $156 |
| Corium, LLC | 7 | $146 |
| Lundbeck LLC | 9 | $139 |
Products named: REXULTI, VRAYLAR, CAPLYTA, AUSTEDO XR, ARISTADA, Dyanavel XR, INVEGA SUSTENNA, INGREZZA.
Industry payments across CA — which companies pay providers there.
